The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales (Q43439315)

23 November 2017

The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales (English)

1 reference

cost-effectiveness analysis

23 November 2017

1 reference

1 reference

Edmunds WJ

1

1 reference

23 November 2017

Brisson M

series ordinal

2

1 reference

23 November 2017

Rose JD

series ordinal

3

1 reference

23 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

23 November 2017

1 reference

23 November 2017

19

1 reference

23 November 2017

23-24

1 reference

23 November 2017

3076-3090

1 reference

Herpes zoster and its complications in Italy: an observational survey

23 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Population-based study of herpes zoster and its sequelae

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

The sequelae of herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

The varicella vaccine. Prevention of herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

The Nottingham Health Profile as a measure of quality of life in zoster patients: convergent and discriminant validity.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

An analysis of infection control of varicella-zoster virus infections in Addenbrooke's Hospital Cambridge over a 5-year period, 1987-92.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

The cost of treatment for post-herpetic neuralgia in the UK

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Pain and its persistence in herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

Disparity between influenza vaccination rates and risks for influenza-associated hospital discharge and death in Manitoba in 1982-1983

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900044-5

7 January 2021

10.1016/S0264-410X(01)00044-5

Identifiers

DOI

1 reference

23 November 2017

1 reference